104 related articles for article (PubMed ID: 19637089)
1. Primary cerebral lymphoma with a 5-year remission to single-agent corticosteroids.
Kürtüncü M; Tüzün E; Durmuş H; Mutlu M; Akman-Demir G; Eraksoy M
Leuk Lymphoma; 2009 Sep; 50(9):1552-3. PubMed ID: 19637089
[No Abstract] [Full Text] [Related]
2. [Primary lymphoma of the central nervous system. Multiple remission with corticosteroid therapy].
Tourniaire D; Pagès M; Blard JM; Pagès A; Labauge R
Rev Neurol (Paris); 1993; 149(3):222-4. PubMed ID: 8235218
[TBL] [Abstract][Full Text] [Related]
3. [Primary central nervous system lymphomas. Diagnostic and prognostic effect of steroid-induced remission].
Cuny E; Loiseau H; Cohadon F
Neurochirurgie; 1998 Mar; 44(1):19-24. PubMed ID: 9757313
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Chamoun K; Choquet S; Boyle E; Houillier C; Larrieu-Ciron D; Al Jijakli A; Delrieu V; Delwail V; Morschhauser F; Hoang-Xuan K; Soussain C
Neurology; 2017 Jan; 88(1):101-102. PubMed ID: 27864520
[No Abstract] [Full Text] [Related]
5. Testicular relapse of primary central nervous system lymphoma.
Rajappa SJ; Uppin SG; Digumarti R
Leuk Lymphoma; 2007 May; 48(5):1023-5. PubMed ID: 17487747
[No Abstract] [Full Text] [Related]
6. [Misleading cerebral arterial wall gadolinium-enhancement in malignant lymphoma].
Inoue H; Sakurai K; Kanou Y; Yamada K; Yuasa H
Rinsho Shinkeigaku; 2018 Jul; 58(7):456-459. PubMed ID: 29962444
[TBL] [Abstract][Full Text] [Related]
7. [A 36-year-old woman with primary central nervous system lymphoma diagnosed by twice brain biopsies, showing relapsing and remitting brain lesions].
Takasone K; Kobayashi C; Katoh N; Kaneko T; Shingu K; Ikeda SI
Rinsho Shinkeigaku; 2018 Jul; 58(7):440-444. PubMed ID: 29962441
[TBL] [Abstract][Full Text] [Related]
8. Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.
Doolittle ND; Dósa E; Fu R; Muldoon LL; Maron LM; Lubow MA; Tyson RM; Lacy CA; Kraemer DF; Butler RW; Neuwelt EA
J Clin Oncol; 2013 Nov; 31(31):4026-7. PubMed ID: 24101051
[No Abstract] [Full Text] [Related]
9. Central nervous system lymphoma: a morphological MRI study.
Koubska E; Weichet J; Malikova H
Neuro Endocrinol Lett; 2016 Sep; 37(4):318-324. PubMed ID: 27857050
[TBL] [Abstract][Full Text] [Related]
10. Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.
Holowiecka-Goral A; Hołowiecki J; Giebel S; Stella-Holowiecka B; Krawczyk-Kulis M; Kos K; Lehmann-Kopydłowska A; Dudzinski M; Hałasz M; Preisner W; Cioch M; Piszcz J
Leuk Lymphoma; 2009 Mar; 50(3):478-80. PubMed ID: 19294561
[No Abstract] [Full Text] [Related]
11. Intra-CSF rituximab for lymhomatous meningitis.
Chamberlain MC; Glantz MJ
J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
[No Abstract] [Full Text] [Related]
12. [Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].
Kuittinen O; Siniluoto T; Isokangas M; Turpeenniemi-Hujanen T; Peltonen J; Alahuhta S; Sonkajärvi E
Duodecim; 2013; 129(15):1563-70. PubMed ID: 24163974
[TBL] [Abstract][Full Text] [Related]
13. Is a "vanishing tumor" always a lymphoma?
Bromberg JE; Siemers MD; Taphoorn MJ
Neurology; 2002 Sep; 59(5):762-4. PubMed ID: 12221174
[TBL] [Abstract][Full Text] [Related]
14. Steroid-induced remission in primary malignant lymphoma of the central nervous system.
Todd FD; Miller CA; Yates AJ; Mervis LJ
Surg Neurol; 1986 Jul; 26(1):79-84. PubMed ID: 3715705
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Evaluation in Primary CNS Lymphoma.
Lukas RV; Riedell P; Horowitz PM; Pytel P; Kamson DO
Neurologist; 2018 Mar; 23(2):53-54. PubMed ID: 29494436
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas.
Moise L; Matta C; Hanna C; Pilorge S; Fermé C; Durrbach A; Ribrag V
Leuk Lymphoma; 2011 Mar; 52(3):521-4. PubMed ID: 21133726
[No Abstract] [Full Text] [Related]
17. Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child.
Akyuz C; Aydin GB; Cila A; Akalan N; Soylemezoglu F; Cengiz M; Yazici N; Buyukpamukcu M
Leuk Lymphoma; 2007 Jun; 48(6):1253-5. PubMed ID: 17577799
[No Abstract] [Full Text] [Related]
18. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience.
Yoon DH; Lee DH; Choi DR; Sohn BS; Kim S; Kim SW; Lee JS; Lee SW; Huh J; Suh C
Bone Marrow Transplant; 2011 Jan; 46(1):105-9. PubMed ID: 20383213
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with primary central nervous system lymphoma treated outside clinical trials.
Hart A; Baars JW; Kersten MJ; Brandsma D; van Tinteren H; de Jong D; Spiering M; Dewit L; Boogerd W
Neth J Med; 2014 May; 72(4):218-23. PubMed ID: 24829178
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
